<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00994097</url>
  </required_header>
  <id_info>
    <org_study_id>NGR014</org_study_id>
    <secondary_id>2008-002703-20</secondary_id>
    <nct_id>NCT00994097</nct_id>
  </id_info>
  <brief_title>NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer</brief_title>
  <official_title>NGR014: Randomized Phase II Study of NGR-hTNF in Combination With Standard Chemotherapy Versus Standard Chemotherapy Alone in Previously Untreated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGC Biologics S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AGC Biologics S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to demonstrate superiority in progression-free survival&#xD;
      (PFS) when NGR-hTNF is added to standard chemotherapy regimen (cisplatin/gemcitabine or&#xD;
      cisplatin/pemetrexed) in locally advanced (stage IIIb with supraclavicular lymph node&#xD;
      metastases or malignant pleural or pericardial effusion), metastatic (stage IV) or recurrent&#xD;
      non-small cell lung cancer (NSCLC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will be randomly assigned to a standard chemotherapy regimen plus low-dose&#xD;
      (0.8 mcg/m^2) NGR-hTNF or standard chemotherapy alone, through a centralized randomization&#xD;
      process using the following stratification factors: performance status (0 vs 1) and histology&#xD;
      (squamous vs non-squamous). In both arms the choice between the two chemotherapy regimens&#xD;
      will be based on the histologic subtype: in patients with squamous histology (including also&#xD;
      generic diagnosis of NSCLC without further subtype classification) is recommended&#xD;
      cisplatin/gemcitabine regimen, in patients with nonsquamous histology (including&#xD;
      adenocarcinoma and large-cell carcinoma) is recommended cisplatin/pemetrexed regimen.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2009</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Every 6 weeks during study treatment and every 6 weeks during the follow-up before PD</time_frame>
    <description>PFS evaluated according to Response evaluation criteria in solid tumors (RECIST)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety according to NCI-CTCAE criteria (version 3)</measure>
    <time_frame>from the date of randomization until 28 days after last treatment</time_frame>
    <description>To evaluate safety profile related to NGR-hTNF in combination with standard chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Every 6 weeks during study treatment and every 6 weeks during the follow-up before PD</time_frame>
    <description>Antitumor activity defined as response rate evaluated according to Response evaluation criteria in solid tumors (RECIST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DR)</measure>
    <time_frame>from the time of first recorded evidence of complete response or partial response until the progressive disease objectively documented</time_frame>
    <description>defined as the time that measurement criteria are met for complete response or partial response (whichever status is recorded first) until the progressive disease is objectively documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>from the randomization until to the date of patient death or discontinuation from the study</time_frame>
    <description>Defined as the time from the date of randomization until the date of death due to any cause or the last date the patient was known to be alive</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>A: NGR-hTNF + cisplatin/gemcitabine or cisplatin/pemetrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGR-hTNF with cisplatin/gemcitabine regimen in patients with squamous histology or with cisplatin/pemetrexed regimen in patients with nonsquamous histology</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: cisplatin/gemcitabine or cisplatin/pemetrexed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cisplatin/gemcitabine regimen is administered in patients with squamous histology and cisplatin/pemetrexed regimen is administered in patients with nonsquamous histology</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NGR-hTNF</intervention_name>
    <description>NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every 3 weeks until confirmed evidence of disease progression or unacceptable toxicity occurs</description>
    <arm_group_label>A: NGR-hTNF + cisplatin/gemcitabine or cisplatin/pemetrexed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin: 80 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles</description>
    <arm_group_label>A: NGR-hTNF + cisplatin/gemcitabine or cisplatin/pemetrexed</arm_group_label>
    <arm_group_label>B: cisplatin/gemcitabine or cisplatin/pemetrexed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine: 1,250 mg/m² intravenous infusion on days 1 and 8 every 3 weeks for a maximum of 6 cycles</description>
    <arm_group_label>A: NGR-hTNF + cisplatin/gemcitabine or cisplatin/pemetrexed</arm_group_label>
    <arm_group_label>B: cisplatin/gemcitabine or cisplatin/pemetrexed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed: 500 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles</description>
    <arm_group_label>A: NGR-hTNF + cisplatin/gemcitabine or cisplatin/pemetrexed</arm_group_label>
    <arm_group_label>B: cisplatin/gemcitabine or cisplatin/pemetrexed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Histologically or cytologically documented inoperable, locally advanced (stage IIIb&#xD;
             with supraclavicular lymph node metastases or malignant pleural or pericardial&#xD;
             effusion), metastatic (stage IV) or recurrent NSCLC. Mixed tumors should be&#xD;
             categorized according to the predominant cell type.&#xD;
&#xD;
          2. Age ≥18 years&#xD;
&#xD;
          3. Life expectancy more than 3 months&#xD;
&#xD;
          4. ECOG performance status 0-1&#xD;
&#xD;
          5. At least one unidimensional measurable lesion (as per RECIST criteria)&#xD;
&#xD;
          6. Adequate baseline bone marrow, hepatic and renal function, defined as follows:&#xD;
&#xD;
               -  Neutrophils &gt;1.5 x 10^9/L and platelets &gt; 100 x 10^9/L&#xD;
&#xD;
               -  Bilirubin &lt;1.5 x ULN&#xD;
&#xD;
               -  AST and/or ALT &lt;2.5 x ULN in absence of liver metastasis&#xD;
&#xD;
               -  AST and/or ALT &lt;5 x ULN in presence of liver metastasis&#xD;
&#xD;
               -  Serum creatinine &lt;1.5 x ULN&#xD;
&#xD;
               -  Creatinine clearance (estimated according to Cockcroft-Gault formula) ≥ 50 ml/min&#xD;
&#xD;
          7. Patients may have had prior therapy providing the following conditions are met:&#xD;
&#xD;
               -  Radiation therapy: wash-out period of 28 days&#xD;
&#xD;
               -  Surgery: wash-out period of 14 days&#xD;
&#xD;
          8. Patients must give written informed consent to participate in the study&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Prior chemotherapy or treatment with another systemic anti-cancer agent (for example&#xD;
             monoclonal antibody, tyrosine kinase inhibitor).&#xD;
&#xD;
          2. Patients must not receive any other investigational agents while on study&#xD;
&#xD;
          3. Patients with myocardial infarction within the last six (6) months, unstable angina,&#xD;
             New York Heart Association (NYHA) grade II or greater congestive heart failure, or&#xD;
             serious cardiac arrhythmia requiring medication&#xD;
&#xD;
          4. Uncontrolled hypertension&#xD;
&#xD;
          5. Prolonged QTc interval (congenital or acquired)&#xD;
&#xD;
          6. Patient with significant peripheral vascular disease&#xD;
&#xD;
          7. History or evidence upon physical examination of CNS disease unless adequately treated&#xD;
             (e.g., primary brain tumor, any brain metastasis, seizure not controlled with standard&#xD;
             medical therapy, or history of stroke).&#xD;
&#xD;
          8. Patients with active or uncontrolled systemic disease/infections or with serious&#xD;
             illness or medical conditions, which is incompatible with the protocol&#xD;
&#xD;
          9. Known hypersensitivity/allergic reaction or contraindications to human albumin&#xD;
             preparations or to any of the excipients&#xD;
&#xD;
         10. Any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the study protocol&#xD;
&#xD;
         11. Pregnancy or lactation. Patients - both males and females - with reproductive&#xD;
             potential (i.e. menopausal for less than 1-year and not surgically sterilized) must&#xD;
             practice effective contraceptive measures throughout the study. Women of child-bearing&#xD;
             potential must provide a negative pregnancy test (serum or urine) within 14 days prior&#xD;
             to registration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Lambiase, MD</last_name>
    <role>Study Director</role>
    <affiliation>AGC Biologics S.p.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Nazionale per la ricerca sul cancro</name>
      <address>
        <city>Genoa</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione San Raffaele del Monte Tabor</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo Oncologico</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>October 13, 2009</study_first_submitted>
  <study_first_submitted_qc>October 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2009</study_first_posted>
  <last_update_submitted>September 25, 2018</last_update_submitted>
  <last_update_submitted_qc>September 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NGR-hTNF</keyword>
  <keyword>Randomized controlled trial</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Pemetrexed</keyword>
  <keyword>Carcinoma, non-small cell lung</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

